Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer

Table 3

Statistical correlations between mutational status and the various clinicopathological parameters of the tumors.

	KRAS mutation			PIK3CA mutation			n mutations/case
	Absent	Present		Absent	Present		0	1	2
Age
≤68 years	16	15		28	3		16	11	4
>68 years	18	13	0.798	29	2	1	15	14	2	0.588
Gender
Male	24	11		35	0		22	20	0
Female	10	17	0.02	22	5	0.012	9	12	6	0.004
Size
≤3 cms	18	16		31	3		17	14	3
>3 cms	16	12	0.801	26	2	0.652	14	11	3	0.965
Site
Right colon	9	2		11	0		6	5	0
Left colon	9	6		15	0		9	5	1
Rectum	16	20	0.083	31	5	0.14	16	15	5	0.608
pT
T1	1	3		4	0		1	3	0
T2	33	25	0.319	53	5	1	30	22	6	0.329
Nodal micrometastases
Absent	28	17		44	1		27	17	1
Present	6	11	0.086	13	4	0.017	4	8	5	0.001
Tumor border configuration
Expansive	12	6		18	0		11	7	0
Infiltrative	22	22	0.271	39	5	0.309	20	18	6	0.212
WHO grade
G1	4	5		7	2		4	3	2
G2	24	22		43	3		24	18	4
G3	6	1	0.2	7	0	0.202	3	4	0	0.562
PDC grade
G1	23	13		35	1		23	11	2
G2	7	7		14	0		6	8	0
G3	4	8	0.168	8	4	0.001	2	6	4	0.004
Tumor budding
Absent	17	13		27	3		17	10	3
Present	17	15	0.803	30	2	0.666	14	15	3	0.541
LVI
Absent	21	12		32	1		20	12	1
Present	13	16	0.201	25	4	0.176	11	13	5	0.078
Status
Alive, DOID	25	12		36	1		24	12	1
DOD	9	16	0.019	21	4	0.147	7	13	5	0.006

DOID: died of independent diseases; DOD: died of disease; LVI: lymphovascular invasion.